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Oral administration of L-arginine and captopril in rats prevents
chronic renal failure by nitric oxide production. The effect of oral
supplementation of L-arginine, the substrate of nitric oxide, (1.25 g/liter
water) and captopril (15 mg/liter water) was studied in 5/6 nephrectomized
rats for a period of three months. N-omega-nitro L-arginine, a nitric oxide
synthase inhibitor, was given orally (70 mg/liter water) with or without
L-arginine or captopril. The urinary excretion of nitrite (NO2) + nitrate
(NO3), the known metabolites of nitric oxide, was taken as an index of
nitric oxide production. Chronic renal failure rats were characterized by a
low creatinine clearance, high FENa%, proteinuria, hypertension and a
low urinary excretion of NO2 + NO3: 0.152 0.06 (P < 0.001) nmol/sg
creatinine compared with 0.481 0.004 (P < 0.001) in normal rats and
0.479 0.11 (P < 0.001) in untreated sham-operated rats. Both L-arginine
and captopril were effective in the normalization of all these parameters.
The combination of L-arginine and captopril had no additive effects. The
nitric oxide synthase inhibitor significantly diminished the captopril ben-
eficial effect. It is concluded that chronic renal failure in rats is a low nitric
oxide production state. The supplementation of L-arginine is shown to
overcome this condition. It is suggested that the beneficial effect of
captopril on chronic renal failure is through a specific L-arginine—nitric
oxide synthase—nitric oxide pathway.
Chronic renal failure (CRF) is characterized by progressive loss
of nephrons caused by increased intraglomerular pressure and
hyperfiltration [1]. The loss of autoregulatory ability exposes the
glomeruli to the systemic blood pressure leading to glomerular
hypertrophy and sclerosis.
Controlling both the systemic and intraglomerular pressures
limits the progression of renal insufficiency in both human and
experimental models of CRF. Thus, the hyperfiltration should be
seen as being a homeostatic disturbance and not a maladaptive
response [2].
Nitric oxide (NO), an extensively studied endothelium-derived
relaxing factor, seems to be a very potent regulator of intrarenal
hemodynamics [3—7]. Intrarenal production of NO is not limited
to the endothelium but also extends to the mesangial, inflamma-
tory and other cells [8, 9]. The modulation of systemic and/or
renal NO metabolism appears to be a logical approach to change
the course of CRF. Based on such an assumption, Reyes et al [10]
found that six weeks of oral supplementation with 1% L-arginine
solution in the drinking water started immediately after 7/8 renal
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mass reduction resulted in a complete normalization of GFR,
RPF, FENa%, protein excretion, and in less glomerulosclerosis
and interstitial damage. Furthermore, the circulating L-arginine
(A) level was normal before and at the end of that study. In a
recent micropuncture study, the same group [11] suggested that
the long-term administration of L-arginine in subtotally nephrec-
tomized rats resulted in a reduction of intraglomerular capillary
pressure and efferent arteriolar resistance, probably by an antag-
onizing angiotensin II effect.
Angiotensin converting enzyme (ACE) inhibitors have a bene-
ficial effect on the progression of a remnant kidney CRF model in
rats [12, 13]. This effect is probably due to the reduction of
intraglomerular pressure by efferent arteriolar dilation [141. Sev-
eral groups have shown that ACE inhibitors increase the brady-
kinin-induced release of NO from the endothelium [15, 16].
Furthermore, ACE inhibition caused a substantial amplification
of endothelium-mediated vasomotor responses in vivo [17].
The present work was undertaken to study the effect of oral
supplementation of L-arginine, the substrate of NO, on rats with
reduced renal mass (3 weeks after a two-stage 5/6 nephrectomy)
and which developed hypertrophy of the remnant kidney as well
as proteinuria. Further objectives of this study were to verify if the
effect of ACE inhibitors on the remnant kidney CRF is possibly
mediated by NO and whether the concomitant administration of
captopril with L-arginine might have an additive effect on the
prevention of CRF.
N-omega-nitro-L-arginine, a nitric oxide synthase (NOS) inhib-
itor (I), was given orally with or without L-arginine or captopril to
validate the L-arginine—nitric oxide synthase.—nitric oxide path-
way. The urinary excretion of the known metabolites of NO,
nitrite (NO2) + nitrate (NO3) was taken as an index of NO
production [18, 19].
Methods
The experiments were performed in 110 Sprague-Dawley rats
of both sexes. All animals were housed in metabolic cages in a
12-hour light/dark cycle at 22°C. A 24-hour urine collection was
obtained from each rat for laboratory investigations. Afterwards,
84 rats underwent a two-stage 5/6 nephrectomy (interval of one
week) under ketalar 80 mg/kg body wt and xylazyne 2.5 mg/kg
body wt i.p. general anesthesia. After the second operation, the
rats were allowed to recover and had free access to a standard rat
chow and tap water for drinking. Three weeks later, a 24-hour
urine collection was followed by a blood sample from a femoral
vein which was carried out under light ether anesthesia. These
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urine and blood samples were used later for baseline values.
Twenty-six rats were sham operated. The 5/6 nephrectomized rats
and the sham-operated rats were allocated to the following
experimental groups (equal number of males and females for each
group) for the drug therapy study period.
Group 1. Sham-operated rats, no drug therapy.
Group 2. Sham-operated rats, but the rats drank a solution of
1.25 g/liter L-arginine (Sigma) instead of tap water.
Group 3. Sham-operated rats, but the rats drank a solution of 70
mg/liter N-omega-nitro-L-arginine (Sigma), a NOS inhibitor, in-
stead of tap water.
Group 4. CRF, no drug therapy.
Group 5. CRF, but the drinking water contained L-arginine as
in group 2.
Group 6. CRF, but the drinking water contained the NOS
inhibitor as in group 3.
Group 7. CRF, but the drinking water contained L-arginine as
in group 2 and N-omega-nitro-L-arginine as in group 3.
Group & CRF, but the rats drank a solution of captopril
(Pharmabest-Squibb, Israel) 15 mg/liter.
Group 9. CRF, but the rats drank a solution of captopril as
group 8 plus L-arginine as in group 2.
Group 10. CRF, but the rats drank a solution of captopril as
group 8 plus NOS inhibitor as in group 3.
The drug therapy study period lasted for 12 weeks, during which
24-hour urine collections and blood samples were obtained from
all 10 groups at weeks 4, 8 and 12.
Laboratoty investigations
BUN, creatinine and sodium were determined in all blood
samples by standard methods. In all urine samples (obtained
immediately before drugs were started), creatinine, sodium and
total proteins were also determined by standard laboratory meth-
ods. Creatinine clearance (Car), fractional excretion of sodium
(FENa%) and 24-hour urine protein excretion (Uprot) were calcu-
lated.
Urinary excretion of nitrite (NO2) + nitrate (NO1) was mea-
sured in all urine samples at four weeks and at the end of the study
(at 12 weeks). The normal values were established from the urine
collections obtained before any operation from all 110 rats. The
NO2 + NO3 was determined as previously described 20]. Follow-
ing the reduction of NO3 by a 90-minute incubation in a tilting
bath (37°C), NO2 was determine with Griess reagent using nitrate
reductase from E. coil (prepared in our laboratory) and NADPH
(Sigma) as cofactor. The results are given in nmoles NO2 +
NO3/g creatinine.
Blood pressure
Systolic blood pressure was measured in awake rats by a tail cuff
method (Harvard Instruments, USA) and recorded on a double
channel recorder. Blood pressure was determined in all rats
before the drug study started, that is, three weeks after the last
operation and at 4-, 8- and 12-week intervals.
Statistical analysis
The data are given as mean SD. One-way analysis of variance
(ANOVA) was used for comparison between the different exper-
imental groups at the same time period of study. Student's t-test
with Bonferroni's correction was used to assess significance
between two groups.
Results
Two rats died, one from group 4 (at 9 weeks) and the other
from group 8 (at 5 weeks); their data were not included in the
statistical analysis. The range of the animals' body weight before
the drug therapy study period was 209 to 263 g and became 187 to
276 g at the end of the study.
The BUN, creatinine clearance, FEN%, the 24-hour protein
excretion ans systolic blood pressure values in all groups before
and at 4, 8, and 12 weeks after therapy are given in Table 1, Before
the initiation of different drug therapy protocols, the 5/6-nephrec-
tomized CRF rats were characterized by a significantly lower
creatinine clearance, and higher BUN, FENa%, and protein
excretion levels, compared with the untreated sham-operated rats.
All 5!6-nephrectomized groups had similar BUN, creatinine clear-
ance, FENa%, 24-hour urinary protein excretion and systolic
blood pressure values before the initiation of the different drug
therapies.
The sham-operated rats treated with L-arginine had similar
kidney function as did the untreated sham-operated rats. How-
ever, the blood pressure decreased significantly after four weeks.
The administration of the NOS inhibitor in the sham-operated
rats resulted in hypertension, decreased creatinine clearance and
higher FENa% and protein excretion compared with the untreated
sham-operated rats.
Changes in creatinine clearance
Creatinine clearance measured after three months of therapy in
the groups of 5!6-nephrectomized rats treated with L-arginine,
captopril or captopril + L-arginine (Fig. 1) was 587 48
d/min/100 g body wt (P < 0.001), 566 42 j.d/min/100 g body wt(P < 0.001), and 480 31 1.il/min/100 g body wt (P < 0.001),
respectively, compared with 285 25 i.d/min/100 g body wt in the
untreated 5/6-nephrectomized group.
The addition of nitric oxide synthase inhibitor to L-arginine
diminished the effect of L-arginine (492 12 i.tl/min/100 g body
wt). Its addition to captopril partially prevented the beneficial
effect of captopril (367 31
.tl/minhlOO g body wt). The nitric
oxide synthase inhibitor alone did not change the course of CRF.
All these changes were already present after four weeks of drug
therapy.
Changes in the FENa%
The FENa% of the L-arginine, captopril or captopril + L-
arginine CRF groups was less than 1% throughout the drug study
period (Fig. 2). The untreated CRF rats and the group receiving
nitric oxide synthase inhibitor alone had a high FENa% (> 2%)
throughout the drug study period.
Changes in the daily protein excretion
After three months of therapy, the groups treated with L-
arginine, captopril, and captopril + L-arginine had daily protein
secretion levels of 7.34 4.2 mg/day/100 g body wt (P < 0.001),
28.7 11.9 mg/day/100 g body wt (P < 0.001) and 9.49 2.4
mg/day/100 g body wt (P < 0.001), respectively, compared with
91.8 22.3 mg/day/100 g body wt in the untreated CRF rats (Fig.
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Table 1. BUN, creatinine clearance (Car), FENa, 24-hour protein excretion (Uprot), and systolic blood pressure in the different experimental groups
BUN
Ccr
pJ/min/100 g
Uprot
mg/24 hr/100 g Systolic BP
mg% body wt FENa body wt mm Hg
Sham (N = 10)
Initial 22 2 531 13" 0.37 0.14" 3.1 043b 122 4
4 weeks 22 4" 553 15" 0.44 0.13" 2.2 0.80" 125 ÷ 3"
8 weeks 20 3" 528 18" 0.47 016b 2.9 0.49" 124 4"
12 weeks 20 4" 549 31" 0.40 011b 124 3b
Sham + A (N = 8)
Initial 23 3 511 17 0.45 0.17 2.7 0.18 122 3
4 weeks 25 4 552 21 0.36 0.20 3.2 0.23 113 2"
8 weeks 23 5 583 19 0.41 0.19 3.2 0.18 112 3"
12 weeks 25 4 603 27 0.44 0.23 2.6 0.22 114 2"
Sham + I (N = 8)
Initial 21 3 521 23 0.49 0.14 2.9 0.31 124 4
4 weeks 24 2 461 26C 0.66 0.13 4.1 0.24" 135 3
8 weeks 23 4 435 22" 0.79 0.14 4.4 0.33" 134 2"
12 weeks 26 3 411 23C 0.94 0.21" 6.1 0.54" 139 4C
CRF (N = 12)
Initial 44 3C 324 26C 0.43 0.2 5.08 1.6" 125 7
4 weeks 49 13C 359 25" 1.90 0.9" 23.4 6.1" 141 6"
8 weeks 43 5" 371 33" 2.34 1.11" 29.0 6.31c 140 4"
12 weeks 48 3C 285 25C 2.81 1.40c 91.8 22.3c 152 5
CRF + A (N = 14)
Initial 46 2.3" 371 17" 0.61 0.13 5.64 1.83" 126 5
4 weeks 43 3.1" 533 34'' 0.83 0.20" 6.92 2.7"' 138 3"
8 weeks 44 5.5" 561 24" 0.79 026d 7.59 2.4"' 140 4"
12 weeks 40 4C 587 48" 0.70 014cd 7.34 4.2"' 137 4cd
CRF + I (N = 10)
Initial 42 4C 350 47" 0.54 0.10 5.27 1.93" 128 4
4 weeks 44 3.1" 358 30" 2.29 0.9c 26.1 8.1" 160 9cd
8 weeks 41 3.6" 338 24" 2.67 1.22" 31.1 7.6" 166 5"'
12 weeks 44 3" 281 52" 2.66 1.29" 73.6 16.3c 160 3cd
CRF + A + I (N = 12)
Initial 44 4C 379 29" 0.41 0.11 6.93 1.54" 127 4.5
4 weeks 56 24cd 463 14"' 0.69 017d 7.41 158cd 170 5cd
8 weeks 49 5.5" 483 17" 0.59 017d 21.2 5.58" 151 4"'
12 weeks 43 2.5" 492 12" 0.51 013d 23.7 6.1"' 154 3.1"
CRF + Capt (N = 12)
Initial 53 4.3" 375 28" 0.47 0.19 7.11 2.34" 128 2
4 weeks 46 2.2" 621 28"' 0.71 0.14" 7.31 2.9"' 142 4"
8 weeks 47 3" 594 24cd 0.77 016d 13.3 45C 143 5"
12 weeks 40 24"' 566 42" 0.59 0.14"' 28.7 11.9"' 133 4"'
CRF + Capt + A (N = 12)
Initial 54 6.1" 353 17" 0.63 0.21 6.83 2.2" 130 2"
4 weeks 40 38"' 551 22" 0.64 022d 6.13 21"' 132 7
8 weeks 43 4.2c 22"' 0.83 024cd 111 26cd 120 4d
12 weeks 38 4.1"' 480 27" 0.54 0.09" 9.49 2.4" 121 4"
CRF + Capt + I (N = 10)
Initial 52 5.7" 379 53" 0.48 0.14 7.65 1.4" 127 3
4 weeks 50 4.1" 399 26" 0.52 0.14" 20.6 4.7" 130 25d
8 weeks 49 4x 386 25C 0.78 0.24"' 44.3 7.34"' 126 3"
12 weeks 49 3.3" 367 31"' 0.89 023cd 41.9 53cd 128 4d
The data are given in mean SD.
Abbreviations are: A, L-arginine 1.15 g/liter drinking water; I, N-omega-nitro-L-arginine 70 mg/liter drinking water; Capt, captopril 15 mg/liter
drinking water.
a p < 0.01, h = P < 0.001 by ANOVA for all the experimental groups for the same time study period
C Significantly different from untreated sham-operated rats by Student's t-test with Bonferroni's correction
"Significantly different from untreated CRF rats by Student's t-test with Bonferroni's correction
3). The daily protein excretion in the captopril-treated rats was Blood pressure
significantly higher (P < 0.01) compared with that in the L-
arginine alone or captopril + L-arginine groups. The addition of The blood pressure changes in all experimental groups during
the nitric oxide synthase inhibitor partially prevented the benefi- the study are given in Table 1. The values at the end of the study
cia! effect of either captopril or L-arginine therapy. The presence are depicted in Figure 4. The administration of L-arginine in sham
of nitric oxide synthase inhibitor alone did not influence the operated rats resulted in a significantly lower systolic blood
course of protein excretion in CRF. The same pattern of changes pressure after 4, 8 and 12 weeks of therapy compared with the
were already present as of four weeks of drug therapy. untreated sham-operated rats. The administration of the NOS
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Fig. 1. Creatinine clearance ml/min 100 g body
wt after three months of drug therapy in the
different experimental groups. Abbreviations are:
CRF, chronic renal failure; A, L-arginine; I,
nitric oxide synthase inhibitor; Capt, captopril.
Values are in mean SD. P < 0.001 by
ANOVA for all the experimental groups; x,
significantly different from untreated sham-
operated rats by Student's t-test with
Bonferroni's correction; #, significantly different
from untreated CRF rats by Student's t-test
with Bonferroni's correction.
Fig. 2. The FEN% after three months of drug
therapy in the different experimental groups.
Abbreviations are: CRF, chronic renal failure;
A, L-arginine; I, nitric oxide synthase inhibitor;
Capt, captopril. Values are in mean SD. P <
0.001 by ANOVA for all the experimental
groups; x, significantly different from untreated-
sham operated rats by Student's t-test with
Bonferroni's correction; #, significantly
different from untreated CRF rats by Student's
(-test with Bonferroni's correction
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inhibitor in the sham-operated rats increased the blood pressure
starting from the four weeks of therapy, which lasted throughout
the study period compared with the untreated sham-operated
rats.
The CRF groups treated with L-arginine alone and captopril
alone had lower blood pressure values than the untreated CRF
rats at 4, 8 and 12 weeks. The combination of L-arginine +
captopril resulted in a similar value for blood pressure as in the
untreated sham-operated rats.
Urinaiy NO2 + NO3 excretion
The findings for urinary NO2 + NO3 excretion are given in
Table 2 and Figure 5. The normal values are 0.481 0.004
nmol/JLg creatinine. This value was obtained by pooling all the 110
determinations obtained before any experimental procedure was
done. At the end of the study, the untreated CRF rats had a much
lower NO2 + NO3 excretion 0.152 0.06 nmol/i.tg creatinine,
compared with the normal rat value (P < 0.001) and than in the
untreated sham-operated rats (P < 0.001). Captopril therapy
raised the excretion of NO2 + NO3 to normal values. The CRF
group receiving captopril + L-arginine combined therapy, 0.858
0.061 nmol/g creatinine, showed similar values to those of the
sham-operated rats treated with L-arginine. The addition of the
nitric oxide synthase inhibitor significantly diminished the capto-
pril and/or L-arginine effect. Similar patterns were already found
at four weeks into the drug therapy period.
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Fig. 3. Daily urinaiy protein excretion after three
months of drug therapy in the different
experimental groups. Abbreviations are: CRF,
chronic renal failure; A, L-arginine; I, nitric
oxide synthase inhibitor; Capt, captopril. Values
are in mean SD. P < 0.001 by ANOVA for
all the experimental groups; x, significantly
different from untreated sham-operated rats by
Student's t-test with Bonferroni's correction; #,
significantly different from untreated CRF rats
by Student's t-test with Bonferroni's correction.
Fig. 4. Blood pressure mm Hg after three months
of drug therapy in the different experimental
groups. Abbreviations are: CRF, chronic renal
failure; A, L-arginine; 1, nitric oxide synthase
inhibitor; Capt, captopril. Values are in mean
SD. P < 0.001 by ANOVA for all the
experimental groups; x, significantly different
from untreated sham-operated rats by Student's
t-test with Bonferroni's correction; #,
significantly different from untreated CRF rats
by Student's t-test with Bonferroni's correction.
Discussion
The present study showed that the regimen of oral supplemen-
tation with L-arginine for three months in 5/6 nephrectomized
rats resulted in a complete normalization of the levels of creati-
nine clearance and FENa%, and significantly reduced proteinuria.
These results were accompanied by a relatively good control of
the systemic blood pressure. The effect of L-arginine became
evident at four weeks after the initiation of therapy and remained
unchanged until the end of the study. When a NOS inhibitor was
given in combination with L-arginine, the recovery of renal
function was partially abolished. The NOS inhibitor itself did not
affect the course of renal failure. However, the systolic blood
pressure was higher at four and eight weeks compared with the
untreated CRF rats.
The present study fully confirmed the findings of Reyes et a!
[10] and Katoh et al [11]. In addition, we showed that L-arginine
had a beneficial effect at a much lower dose. Furthermore,
L-arginine therapy was still effective even when started after CRF
was already established.
The kidneys and, particularly, the proximal tubules are a major
site of L-arginine synthesis [21]. A decrease in NO production or
an impaired response to NO may contribute to the initiation or
maintenance of the increased intraglomerular high pressure state.
At three months after 5/6 renal mass reduction, the untreated
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N 4 weeks 12 weeks
Sham 10 0.492 0.11C 0.479 o.lla
Sham + A 8 0.899 020b 1.112 0.21"
Sham + I 8 0.272 0.05" 0.238 0.05"
CRF 12 0.163 0.06" 0.152 0.04"
CRF + A 14 0.622 0.09"' 0.691 0.41"
CRF + I 10 0.224 004" 0.187 0.02"
CRF + A + 1 12 0.403 0.09" 0.391 0.02"
CRF + Capt
CRF + Capt + A
12
12
0.423 0.05""
0.935 0.21"'
0.459 0.07"
0.896 0.07"'
CRF + Capt + I 10 0.254 0.08" 0.203 0.03"
The data are given in mean SD.
Abbreviations are: A, L-arginine 1.15 glliter drinking water; I, N-omega-
nitro-L-arginine 70 mg/liter drinking water; Capt, captopril 15 mg/liter
drinking water.
P < 0.001 by ANOVA for all the experimental groups at the same time
study periodb Significantly different from untreated sham-operated rats by Student's
t-test with Bonferroni's correction
"Significantly different from untreated CRF rats by Student's t-test with
Bonferroni's correction
CRF rats were characterized by an almost threefold lower daily
urinary NO2 + NO3 (nmoI/tg creatinine) excretion, compared to
both the normal rats and the sham-operated untreated rats. This
effect was already present at four weeks.
These findings favor the hypothesis that the experimental CRF
caused by severe renal mass reduction is characterized by a low
renal NO production. There is no evidence that L-arginine
synthesis is lower in CRF [21]. Also, circulating L-arginine levels
are within the normal range in 7/8 nephrectomized rats [10].
A potent nitric oxide synthase inhibitor has been isolated from
human plasma [22]. Its elimination is impaired in chronic renal
failure.
Recently, in vitro experiments showed that the potency of
naturally occurring inhibitor(s) of NOS in renal insufficiency was
Fig. 5. NO2 + NO3 nmo1/sg creatinine after
three months of drug therapy in the different
e.sperimental groups. Abbreviations are: CRF,
chronic renal failure; A, L-arginine; I, nitric
oxide synthase inhibitor; Capt, captopril. Values
are in mean so. P < 0.001 by ANOVA for
all the experimental groups; x, significantly
different from untreated sham-operated rats by
Student's t-test with Bonferroni's correction; #,
significantly different from untreated CRF rats
by Student's t-test with Bonferroni's correction.
overcome by increasing the arginine concentration [231. Presum-
ably, the addition of NO substrate in uremic rats may overcome
the effect of this inhibitor, suggesting an inappropriately low renal
NO substrate level. In favor of this hypothesis was the high urinary
excretion of NO metabolites in the 5/6 nephrectomized rats
treated with L-arginine as well as in the sham-operated animals
treated with L-arginine.
This effect was significantly diminished with the addition of the
exogenous nitric oxide synthase inhibitor.
Oral captopril administration in the 5/6 nephrectomized rats
resulted in similar beneficial effects, as was found in the group
treated by L-arginine. As in the L-arginine treated 5/6 nephrecto-
mized rats, the effect of captopril was already present at four weeks
of therapy and remained unchanged for the duration of the study.
The combination of captopril with the NOS inhibitor signifi-
cantly diminished the captopril effect. The administration of both
captopril and L-arginine resulted in a good recovery of renal
function in CRF rats and a complete normalization of blood
pressure at the end of the study. ACE inhibitors have been used
in the prevention of experimental CRF. These drugs could reduce
proteinliria, hypertension and the loss of renal function. The
present study showed, as had been reported by others [121, that
the administration of ACE inhibitors in the remnant kidney rats
resulted in almost complete recovery of GFR, less proteinuria and
good control of the systemic blood pressure.
These changes seem to be mediated by a specific effect on NO
production. First, the concomitant administration of NOS inhib-
itor with captopril partially prevented the beneficial effects of the
ACE inhibitor, Second, the long-term captopril administration
resulted in a high NO2 + NO3 urinary excretion in the 5/6
nephrectomized rats, which was inhibited in the captopril + NOS
inhibitor-fed rats. The same pattern of nitrite/nitrate urinary
excretion was observed in the 5/6 nephrectomized rats treated
with L-arginine or treated with captopril.
Several groups have shown that the ACE inhibitors increase the
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Table 2. NO2 + NO3 urinary excretion (nmol/,tsg creatinine) at 4 weeks
and at the end of the study in the different experimental groups
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bradykinin-induced release of NO and prostaglandin Pg12 from the
endothelium [15, 24]. Zanzinger, Zheng and Bassenge [17] demon-
strated that ACE inhibitors cause an important increase of endothe-
hum-mediated vasomotor responses in vivo: the endothelium sensi-
tivity to receptor-dependent agonists may be augmented by an
enhancement of the effects of endogenously formed bradykinin.
ACE inhibitors [14, 25] and nitric oxide [7, 11] were found to
produce glomerular efferent arteriolar vasodilation. This may be a
plausible explanation of the reduction of the intraglomerular
hypertensive state found in experimental CRF rats. Both NO and
captopril probably buffer the vasoconstrictive influence of endo-
genous angiotensin, particularly in the kidney [4, 25].
The increase in the fractional excretion of sodium in chronic
renal failure is proportional to the decline in GFR, without any
increase in extracellular or plasma volume. The normalization of
the renal fractional excretion of sodium by the administration of
L-arginine or captopril may be explained by the normalization of
GFR; however, a direct tubular effect on sodium transport of both
drugs cannot be excluded.
The exact mechanism controlling the reduction of proteinuria
by captopril/nitric oxide is not known. The possibility of an effect
on glomerular basement membrane, mesangial contraction and
macromolecular transport changes were already attributed to the
ACE inhibitors in a remnant kidney CRF model [13].
Although a histological study was done, both captopril [12] and
L-arginine therapy [10] were found to be associated with less
glomerulosclerosis in the remnant CRF model. The known anti-
platelets aggregating effect of NO [23] may be one of mechanisms
that prevents glomerular and interstitial damage.
L-arginine and captopril either alone or combined significantly
reduced the systemic blood pressure. The question of whether the
systemic blood pressure or the intraglomerular hypertension are
isolated or combined pathogenetic factors in the development of
chronic renal insufficiency is still not fully answered. However, the
beneficial effect of ACE inhibitors [12] and L-arginine [10] in the
prevention of chronic renal failure was observed either with or
without the normalization of the systemic hypertension.
The development of hypertension in chronic renal failure has
been attributed to the accumulation of an endogenous nitric oxide
synthase inhibitor [22]. Increasing the NO production by L-
arginine or captopril may overcome the effect of such a NOS
inhibitor and may also offer a possible explanation of the systemic
hypotensive effects of these drugs.
In conclusion, chronic renal failure is a low nitric oxide produc-
tion state. The chronic administration of L-arginine has beneficial
effects on kidney function, possibly by adding the necessary
substrate to the endothelial cells damaged by the resultant
microcirculatoiy changes. Captopril acts via the NO synthesis
pathway in order to prevent the deterioration of renal function.
Reprint requests to Dr. Adrian laina, Department of Nephrology, Tel-Aviv
Sourasky Medical Center, Ichilov Hospital 6 Weizman St., Tel-Aviv 64239,
Israel.
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